Victor Golmer Novo Nordisk ( NVO ) and Viatris ( NASDAQ: VTRS ) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo’s popular weight-loss drugs Wegovy and Ozempic.
The companies announced the settlement in a joint filing on Friday made with the U.S. Patent.
